Rechallenge immunotherapy after immune resistance in patients with advanced thymic carcinoma
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03597-z ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Keda Shao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate training base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, China. Hauptthemen laut MEDLINE: Thymus Neoplasms, Thymoma, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Foundation of CSCO-Shiyao, Science Fund for Distinguished Young Scholars of Zhejiang Province, Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents.
Abstract (Originalsprache)
BACKGROUNDS: Immunotherapy is effective for patients with advanced thymic carcinoma (TC). However, the effectiveness of rechallenge immunotherapy in patients who are resistant to immunotherapy has not been investigated. METHODS: Thirty-five patients with advanced TC using immunotherapy between 2016 and 2023 at Zhejiang Cancer Hospital, The Second Affiliated Hospital of Nanchang University, and Fujian Cancer Hospital were evaluated in this study. Tumor response was evaluated according to the Response Evaluation Criteria in Solid Tumors version 1.1. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method. RESULTS: A total of 35 patients were included in this study. The median PFS (mPFS) for all patients was 5.43 months and the median OS (mOS) was 16 months. After rechallenge immunotherapy, only three patients achieved partial response, resulting in an overall response rate of 16.7%, and nine patients attained stable disease, resulting in a disease control rate of 66.7%. Patients who underwent rechallenge immunotherapy had shorter mPFS compared to chemotherapy (3.53 months vs. 6.00 months, P = 0.041). In addition, the incidence of Grade 3-4 treatment-related adverse events in these patients was 22.2%. CONCLUSION: Rechallenge immunotherapy has poor efficacy in immunotolerant TC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Postgraduate training base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, China.
- Department of Clinical Trial, The Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
- Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, The Third Affiliated Hospital of Jiaxing University, Jiaxing, 314000, Zhejiang, People's Republic of China. xuchunweibbb@163.com.
- Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, China. xuchunweibbb@163.com.
- Postgraduate training base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, China. songzb@zjcc.org.cn.
- Department of Clinical Trial, The Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, 310022, China. songzb@zjcc.org.cn.
Förderung
- Foundation of CSCO-Shiyao
- Science Fund for Distinguished Young Scholars of Zhejiang Province
- Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents
Zitieren
APA
Shao, K., Zeng, X., Hao, Y., Wang, Y., Xu, C., & Song, Z. (2024). Rechallenge immunotherapy after immune resistance in patients with advanced thymic carcinoma. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03597-z
Vancouver
Shao K, Zeng X, Hao Y, Wang Y, Xu C, Song Z. Rechallenge immunotherapy after immune resistance in patients with advanced thymic carcinoma. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03597-z
BibTeX
@article{Shao2024,
author = {Shao, Keda and Zeng, Xiaohong and Hao, Yue and Wang, Yanhua and Xu, Chunwei and Song, Zhengbo},
title = {Rechallenge immunotherapy after immune resistance in patients with advanced thymic carcinoma},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03597-z}
}
EUVIMED